Menarini

Focus: Menarini is a private German biotech company headquartered in Dresden specializing in small-molecule therapeutics across oncology, cardiovascular, gastroenterology, metabolic, and respiratory indications. The company operates with highly concentrated revenue from a single marketed product.

Oncology Cardiovascular Gastroenterology Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PRIVATE

Open Jobs

About Menarini

AI assessmentNot Hiring

No open roles listed right now. Follow Menarini to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

RANEXA

Coronary Artery Disease, Angina Pectoris, Myocardial Ischemia

$2M Part D

LOE Approaching

Sole revenue generator representing 100% of company revenue; approaching patent expiration poses existential business risk without pipeline success.

Products & Portfolio (1)

Help build intelligence for Menarini

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Watch Out For

Extreme revenue concentration risk: 100% of revenue from RANEXA, which faces approaching loss of exclusivity with no disclosed LOE date, creating near-term cash flow vulnerability
Zero active job postings signal no current hiring momentum, suggesting organizational retrenchment or early-stage growth phase without external recruitment activity
Pipeline quality concerns: majority of programs are Phase 1-2 stage with scattered indications; many appear to be exploratory or repurposed compounds rather than differentiated assets

Pipeline & Clinical Trials

Continuous glucose monitoring for immediate correction of abnormal glycemia

Diabetes

N/A

Clinical Trials (1)

NCT00878891Real-time Continuous Glucose Monitoring in Diabetic Cardiothoracic Surgery Patients

N/A

SGS education

Diabetes Mellitus

N/A

Clinical Trials (1)

NCT00391040SGS: a Structured Treatment and Teaching Programme for Elderly Patients With Diabetes Mellitus

N/A

Selinexor

Multiple Myeloma

N/A

Clinical Trials (1)

NCT05954780Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma

N/A

Nutraceutical combination

Hypercholesterolemia

N/A

Clinical Trials (1)

NCT03739242Effect of a Treatment With a Nutraceutical Combination on Sub-optimal LDL Cholesterol Levels

N/A

A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients

Metastatic Breast Cancer (MBC)

N/A

Clinical Trials (1)

NCT06833853A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients

N/A

Vascular microdialysis using the GMD-system

Type 1 Diabetes

N/A

Clinical Trials (1)

NCT01709851Performance Study to Test the GlucoMen®Day System Using Intravascular and Subcutaneous Microdialysis in Subjects With Type 1 Diabetes

N/A

Liquid Biopsy

Metastatic Breast Cancer

N/A

gluten-free, normocaloric diet from 6 to 12 months

Celiac Disease

N/A

Clinical Trials (1)

NCT00639444Risk of Celiac Disease and Age at Gluten Introduction

N/A

Pigment Solution Program

Melasma

N/A

Clinical Trials (1)

NCT06174545Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma

N/A

motivational interviewing

Type1diabetes

N/A

Clinical Trials (1)

NCT03906786Motivational Interviewing and Self-care in Type 1 Diabetes: Randomized Controlled Clinical Trial.

N/A

Responses to CPET in Subjects With Persistent Exercise Intolerance After COVID-19: an Open-Source Ex

COVID-19

N/A

Nebivolol

Heart Failure

N/A

Clinical Trials (1)

NCT02619526Comparative Effects of Nebivolol and Carvedilol on Diastolic Function in the Elderly Heart Failure Patients

N/A

Systematic detection of vascular risk factors and subsequent evidence-based treatment

Stroke

N/A

Continuous glucose monitoring

Stress

N/A

Clinical Trials (1)

NCT00740012Glycemic Rises After Waking Up In Response To An Alarm Clock In Type 1-Diabetic Patients Analysed With Continuous Glucose Monitoring (GlucoDay®)

N/A

A mix of bioactive natural compounds

Cognitive Dysfunction

N/A

Clinical Trials (1)

NCT03825042Effect of an Antioxidants Mix on Cognitive Performance and Well Being: The Bacopa, Licopene, Astaxantina, Vitamin B12

N/A

Cell-based non-invasive prenatal testing

Prenatal Screening

N/A

Clinical Trials (1)

NCT05671744Fetal Cell Analysis From Maternal Blood

N/A

CellSearch Circulating Tumor Cells

Metastatic Breast Cancer

N/A

Clinical Trials (1)

NCT05662345ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)

N/A

Torasemide tablet 10 mg

Healthy Adult Male and Female Volunteers

Phase 1

Clinical Trials (1)

NCT07201584A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions:

Phase 1

Tamsulosin

Healthy Adult Males Volunteers

Phase 1

Clinical Trials (1)

NCT07146711A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State

Phase 1

Tamsulosin

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT07091669A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed Conditions

Phase 1

GlucoMenDay

Type 1 Diabetes

Phase 1

Clinical Trials (1)

NCT01407315Accuracy, Reliability and Safety of GlucoMen®Day, a New Generation Microdialysis Continuous Glucose Monitor

Phase 1

Nepadutant

Infantile Colic

Phase 1

Clinical Trials (1)

NCT00655083A Phase I Study to Evaluate the Oral Absorption of Nepadutant in Infants

Phase 1

MEN1611

Advanced or Metastatic Breast Cancer

Phase 1

Clinical Trials (1)

NCT03767335MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

Phase 1

Enantyum® oral solution

Acute Pain

Phase 1

Clinical Trials (1)

NCT02209454Comparative Bioavailability of Dexketoprofen Trometamol Oral Solution vs Tablet Formulations

Phase 1

MEN1309

Metastatic Solid Tumors

Phase 1

Clinical Trials (1)

NCT03403725MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study

Phase 1

MEN1112

Recurrent Adult Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT02353143Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Ibuprofen 2%

Healthy Male and Female Subjects

Phase 1

Clinical Trials (1)

NCT07036861A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension

Phase 1

Tamsulosin

Healthy Volunteer Male Subjects

Phase 1

Clinical Trials (1)

NCT07156916A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting Conditions

Phase 1

Levothyroxin

Healthy

Phase 1

Clinical Trials (1)

NCT06547242Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose Administration

Phase 1

Samuraciclib

Metastatic Breast Cancer

Phase 1/2

MEN1611

Metastatic Colorectal Cancer

Phase 1/2

Clinical Trials (1)

NCT04495621MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

Phase 1/2

MEN1703

Acute Myeloid Leukemia

Phase 1/2

Clinical Trials (1)

NCT03008187MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia

Phase 1/2

Febuxostat

Tumor Lysis Syndrome

Phase 1/2

Clinical Trials (1)

NCT03605212Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults

Phase 1/2

Ranolazine PR

HCM - Hypertrophic Non-Obstructive Cardiomyopathy

Phase 2

Clinical Trials (1)

NCT03953989Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy

Phase 2

Nepadutant

Colic

Phase 2

Clinical Trials (1)

NCT01532518Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance

Phase 2

Fasitibant- low dose

Knee Osteoarthritis

Phase 2

Clinical Trials (1)

NCT02205814Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee

Phase 2

Ibodutant

Irritable Bowel Syndrome

Phase 2

Clinical Trials (1)

NCT00761007Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)

Phase 2

Ibodutant

Irritable Bowel Syndrome With Diarrhea

Phase 2

Clinical Trials (1)

NCT01303224Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)

Phase 2

MEN1703

Non-Hodgkin Lymphoma, B-cell

Phase 2

Clinical Trials (1)

NCT06534437MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Phase 2

Dexketoprofen Trometamol

Pain

Phase 2

Clinical Trials (1)

NCT01307020Analgesic Effect of Different Combinations of Dexketoprofen Trometamol With Tramadol Hydrochloride in a Model of Moderate to Severe Pain

Phase 2

MEN1611

Breast Cancer

Phase 2

Clinical Trials (1)

NCT05810870PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

Phase 2

Elacestrant

Breast Cancer

Phase 2

Clinical Trials (1)

NCT07159451A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer

Phase 2

Capecitabine

Estrogen-receptor-positive Breast Cancer

Phase 2

Meropenem plus vaborbactam

Gram Negative Infections

Phase 2

Clinical Trials (1)

NCT06828848A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections

Phase 2

MEN16132 - 0.125 mg

Osteoarthritis, Knee

Phase 2

Clinical Trials (1)

NCT01091116A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS

Phase 2

Ranolazine

Persistent Atrial Fibrillation

Phase 2

Clinical Trials (1)

NCT01534962Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion